To understand additional mechanisms of resistance to ICB intervention and the potential utility of the humanized model to provide novel insights regarding tumor immune escape, we performed transcriptome profiling by RNA-sequencing (RNA-seq) of PW samples from mice that responded to aPD1/CTLA4 along with IgG controls (day 53 in figure 5B), solid tumors from treated mice that relapsed after re-challenge (online supplemental figure S6C), as well as control animals treated with PBS (figure 5B). The gene discussed is CTLA4; the disease is neoplasm.